CYP19A1 and breast cancer: A randomized, placebo-controlled trial confirmed that the expression of aromatase, the rate-limiting enzyme in estrogen biosynthesis, was increased in the breast tissue of obese patients, which led to an elevated risk of HR+ BC in obese postmenopausal women and docosahexaenoic acid could reduce the expression of aromatase (66).